Table 1.
Patients characteristics at the cross-sectional phase visit
| Total | Partly controlled | Uncontrolled | |
|---|---|---|---|
| Number of patients, n (%) |
1017 (100) |
451 (44.3) |
566 (55.7) |
| Age, years, mean (SD) |
46 (15) |
45 (15) |
47 (15) |
| Gender, n (%) |
|
|
|
| Males |
343 (33.7) |
160 (35.5) |
183 (32.3) |
| Females |
674 (66.3) |
291 (64.5) |
383 (67.7) |
| Duration of asthma, years, mean (SD) |
17.4 (13.0) |
16.4 (12.7) |
18.2 (13.2) |
| Body mass index categories, n (%) |
|
|
|
| Obese (≥ 30 kg/m2) (1) |
201 (19.8) |
75 (16.6) |
126 (22.3) |
| Overweight (≥ 25 and < 30 kg/m2) |
357 (35.1) |
162 (35.9) |
195 (34.5) |
| Normal weight (≥ 18.5 and < 25 kg/m2) |
390 (38.4) |
188 (41.7) |
202 (35.7) |
| Underweight (< 18.5 kg/m2) |
32 (3.2) |
12 (2.7) |
20 (3.5) |
| Not available |
37 (3.6) |
14 (3.1) |
23 (4.1) |
| Smoking habits, n (%) |
|
|
|
| Current smokers |
197 (19.4) |
77 (17.1) |
120 (21.2) |
| Non-smokers |
637 (62.6) |
287 (63.6) |
350 (61.8) |
| Ex-smokers (2) |
174 (17. 1) |
86 (19.1) |
88 (15.6) |
| Not available |
9 (0.9) |
1 (0.2) |
8 (1.4) |
| Concomitant diseases (3), n (%) |
|
|
|
| Total |
640 (62.9) |
287 (63.6) |
353 (62.4) |
| Rhinitis |
362 (35.6) |
164 (36.4) |
198 (35.0) |
| Cardiovascular diseases |
151 (14.8) |
70 (15.5) |
81 (14.3) |
| Gastro-oesophageal reflux |
171 (16.8) |
68 (15.1) |
103 (18.2) |
| Sinusitis (4) |
114 (11.2) |
38 (8.4) |
76 (13.4) |
| Nasal polyposis |
52 (5.1) |
25 (5.5) |
27 (4.8) |
| Type 2 diabetes |
39 (3.8) |
14 (3.1) |
25 (4.4) |
| Respiratory infections |
43 (4.2) |
15 (3.3) |
28 (5.0) |
| Psychological disturbances |
25 (2.5) |
9 (2.0) |
16 (2.8) |
| Type 1 diabetes |
5 (0.5) |
2 (0.4) |
3 (0.5) |
| Other diseases |
108 (10.6) |
42 (9.3) |
66 (11.7) |
| Quality of life, n |
1010 |
448 |
562 |
| EQ-5D (5) score, mean (SD) |
0.72 (0.2) |
0.75 (0.2) |
0.69 (0.2) |
| EQ-5D (5) VAS score, mean (SD) | 65.1 (15.6) | 68.6 (14.9) | 61.5 (16.3) |
(1) Overall p = 0.021; (2) Patients who stopped smoking since at least one year; (3) Patients could have more than one concomitant disease; (4) Overall p = 0.012; (5) EQ-5D: EuroQoL-5D questionnaire.